Clinical significance of p53 alterations in surgically treated prostate cancers
暂无分享,去创建一个
A. Haese* | G. Sauter | J. Köllermann | T. Schlomm | R. Simon | S. Minner | M. Graefen | T. Steuber | H. Huland | A. Erbersdobler | M. Mirlacher | Birte Jessen | P. Kirstein | K. Milde‐Langosch | L. Iwers | A. Passow-Drolet
[1] Magdi Kirollos,et al. Re: Axel Heidenreich, Gunnar Aus, Michel Bolla, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80. , 2008, European urology.
[2] J. Gregg,et al. Profiling of gene expression changes caused by p53 gain‐of‐function mutant alleles in prostate cancer cells , 2005, The Prostate.
[3] Jason A. Koutcher,et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.
[4] L. Bubendorf,et al. Expression patterns of potential therapeutic targets in prostate cancer , 2005, International journal of cancer.
[5] G. Viale,et al. The clinical significance of p53 aberrations in human tumours , 2004, Virchows Archiv.
[6] Ronald Simon,et al. Tissue microarrays in drug discovery , 2003, Nature Reviews Drug Discovery.
[7] M. Graefen,et al. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy , 2003, Journal of Cancer Research and Clinical Oncology.
[8] R. deVere White,et al. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. , 2003, Cancer research.
[9] W. Zhang,et al. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein , 2003, Prostate Cancer and Prostatic Diseases.
[10] A. Giordano,et al. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] K. Pienta,et al. Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis , 2002, The American journal of surgical pathology.
[12] M. Graefen,et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. , 2002, European urology.
[13] C. Abbou,et al. EAU guidelines on prostate cancer. , 2009, European urology.
[14] H. Moch,et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.
[15] A. Partin,et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.
[16] J. Overgaard,et al. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. , 2000, The Journal of urology.
[17] J. Wilson,et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. , 2000, Cancer research.
[18] John T. Wei,et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. , 1999, The Journal of urology.
[19] T C Gasser,et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.
[20] M. Rubenstein,et al. An evaluation of the markers p53 and Ki‐67 for their predictive value in prostate cancer , 1998, Journal of surgical oncology.
[21] M. Kattan,et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. , 1998, Cancer.
[22] L. Cox. Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1 , 1997, The Journal of pathology.
[23] R. Cote,et al. p53 protein and gene alterations in pathological stage C prostate carcinoma. , 1997, The Journal of urology.
[24] D. Grignon,et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. , 1997, Journal of the National Cancer Institute.
[25] J. Brooks,et al. An uncertain role for p53 gene alterations in human prostate cancers. , 1996, Cancer research.
[26] J. Moul,et al. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] H. Huland,et al. Immunohistochemical detection of p53 protein in human prostatic cancer. , 1994, The Journal of urology.
[28] W. W. Nichols,et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. , 1993, Journal of the National Cancer Institute.
[29] T. Visakorpi,et al. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.
[30] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.